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Measuring Airway Mucin 2 in Patients with Severe
Chronic Obstructive Pulmonary Disease with
Bacterial Colonization
To the Editor:
Sibila and colleagues reported an analysis of the levels of the
secreted polymeric mucins MUC2, MUC5AC, and MUC5B in the
sputum and bronchoalveolar lavage fluid of patients with severe
chronic obstructive pulmonary disease (COPD) (1). We are writing
because they found a very high level of MUC2 in both specimens,
whereas most recent studies by others find little or no MUC2 in
the airway. Therefore, this report raises the possibility of an error
in measurement that could cause confusion in the field.
Specifically, the authors found levels of MUC2 in lavage fluid
1.3-fold higher than MUC5B and 101-fold higher than MUC5AC.
Similarly, they found levels of MUC2 in sputum 4.3-fold higher
than MUC5B and 77-fold higher than MUC5AC. In contrast, a
quantitative comparison of mucin transcripts in mouse lungs in
healthy conditions found Muc2 levels only 0.35% those of Muc5b
and 10% those of Muc5ac, which is expressed in mice at a low level
at baseline (2). During allergic inflammation, Muc5ac increased
43-fold, whereas Muc2 did not increase significantly. Mouse
proximal airways resemble human distal rather than proximal
airways, but these data suggest that Muc2 is a minor polymeric
mucin in the mammalian airway if it is present at all. Supporting
this, mass spectrometry analysis of horse tracheal mucus showed
no Muc2 peptides, and reverse transcriptase–polymerase chain
reaction of tracheal epithelium showed no Muc2 transcripts (3).
In human specimens, mass spectrometry analysis of sputum from
healthy subjects and apical secretions from normal bronchial epithelial
cell cultures identified MUC5AC and MUC5B but no MUC2 (4).
Quantitative immunoblotting of sputum from normal subjects and
patients with asthma, cystic fibrosis, or COPD using mucin-specific
antisera detected MUC2 in only 6 out of 44 samples (5). In that study,
the levels of MUC2 ranged from 0.2 to 2.5% of the total mucin content
in the six positive samples and were obtained from one normal
subject, two subjects with COPD, and three subjects with asthma.
In a subsequent study by the same group, quantitative
immunoblotting of sputum specimens from 15 patients with COPD
and 17 smokers without airflow obstruction showed MUC5AC and
MUC5B at substantial levels in all samples, but MUC2 in only two
COPD samples and one smoker sample, and only at very low levels
(6). In unpublished work from the SPIROMICS (Subpopulations
and Intermediate Outcome Measures in COPD Study) study, one of
us (M.K.) performed a quantitative (label-free) mass spectrometry
analysis of sputum samples from 20 healthy subjects and 46 subjects
with severe COPD and found that the mean level of MUC5B is
higher than that of MUC5AC by approximately 10-fold in healthy
subjects and 3-fold in subjects with COPD, and MUC5B is higher
than MUC2 by more than 1,000-fold in both groups.
In their Methods section, Sibila and colleagues state that
MUC2,MUC5AC, andMUC5B were measured by validated ELISA
kits from USCN Life Science, Inc., Wuhan, China, but neither
this (1) nor their previous manuscript cited therein provide
experimental details other than the limits of detection and that the
manufacturer’s instructions were followed. The authors note
that “previous studies have suggested concerns about accurate
measurements of MUC2, indicating that some results should be
considered with caution,” with which we agree. Possible causes of
inaccurate measurement include cross-reacting antibodies or the
degradation of mucin epitopes precluding immunodetection. The
most reliable data at the protein level are probably obtained by
quantitative immunoblotting or mass spectrometry, and these
indicate that MUC2 is at most a minor component of airway
mucus in health and in the inflammatory diseases examined to
date. In contrast to these findings in mammalian airways, MUC2
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From the Authors:
We thank Dickey and colleagues for their interest in our recently
published article on the secreted polymeric mucins levels in the
sputum and bronchoalveolar (BAL) fluid of patients with severe
chronic obstructive pulmonary disease (COPD) with and without
bacterial airway colonization (1). Dickey and colleagues expressed
surprise at the high levels of MUC2 in the airways of our patients
with COPD, which is contrary to their previous studies (2, 3).
We agree this was a surprising finding, and we discussed this
extensively in the article, in which we mentioned previous studies in
asthma, cystic fibrosis, and COPD that suggested higher levels of
MUC5AC and MUC5B relative to MUC2 prior studies. As ours was
a surprising finding in a relatively small cohort, we make clear in the
article that low sample size limits the generalizability of the results
and that the findings need to be confirmed in other cohorts.
The aim of our study was to compare the secreted mucin levels
among colonized and noncolonized patients with COPD (study design
registered at www.clinicaltrials.gov as NCT01976117) rather than to
quantify different mucin levels in the COPD airway. For that purpose,
we used commercial ELISA kits (USCN Life Science, Inc., Wuhan,
China) previously validated by our group (4) and others (5).
Experimental details were: (1) 100 ml of seven standard
dilutions; blank and each sample were incubated into single
precoated well for 2 hours at 378C. (2) Liquid was removed and
100 ml of detection reagent A were added and incubated for 1 hour
at 378C. (3) Detection reagent A was removed and wells were
washed three times with 300 ml of 13 wash solution per time.
(4) 100 ml of detection reagent B were added and incubated for
30 minutes at 378C. (5) Detection reagent B was removed and
washed five times with 300 ml of 13 wash solution per time. Then
90 ml of substrate solution was added to each well an incubated
for 15 minutes at 378C. (6) 50 ml of stop solution was added to each
well, and optical density was immediately measured at 450 nm. To
avoid degradation of mucin protein during incubation at 378C,
supernatant was supplemented with protease inhibitor cOmplete
ethylenediaminetetraacetic acid–free (Roche, Indianapolis, IN) before
analysis. To discard cross-reacting antibodies, three recombinant
proteins, MUC2, MUC5AC, and MUC5B, supplied by the
manufacturer, were used as quality control (positive/negative,
respectively) on every ELISA test. This would make inaccurate
measurement due to cross-reactivity of antibodies unlikely, and we
made appropriate efforts to reduce the risk of degradation of mucins.
Using this methodology, MUC2 was detected in 42 BAL
fluid samples and in 43 sputum samples from 45 stable patients with
severe COPD (1). In addition, a positive correlation was identified
among MUC2 levels from sputum and BAL samples from stable
patients with COPD (1). Furthermore, sputum MUC2 levels had a
direct relationship with FEV1% predicted in COPD (1).
Although all of these findings suggest a proper mucin detection,
we agree with Dickens and colleagues that some results should be
considered with caution due to previously reported concerns in
MUC2 measurements (6), as we stated in our limitations section.
Further studies are needed to confirm these results that, in our
opinion, suggested a potential association of MUC2 with bacterial
colonization in chronic airway respiratory diseases.
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